(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 3 November 2005 (03.11.2005)

PCT

(10) International Publication Number WO 2005/103054 A2

- (51) International Patent Classification⁷: C07D 487/08, A61K 31/4995, A61P 37/00
- (21) International Application Number:

PCT/EP2005/004422

- (22) International Filing Date: 25 April 2005 (25.04.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

0409236.7 26 April 2004 (26.04.2004) GB

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HENG, Richard [FR/FR]; 19, passage de la Colline, F-68220 Hegenheim (FR). RÉVÉSZ, Lászlo [CH/CH]; Ob dem Fichtenrain 7, CH-4106 Therwil (CH). SCHLAPBACH, Achim [DE/DE]; Hünerbergweg 8, 79539 Lörrach (DE). WÄLCHLI, Rudolf [CH/CH]; St. Johanns-Vorstadt 90, CH-4056 Basel (CH).


- (74) Agent: LEON, Susanna; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS AS CCRI ANTAGONISTS



(57) Abstract: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.